Precigen Reports Full Year 2024 Financial Results and Business Updates
Portfolio Pulse from
Precigen, Inc. reported its full year 2024 financial results and business updates. The FDA has granted priority review to its BLA for PRGN-2012, with a PDUFA target action date set for August 27, 2025. The company is preparing for a potential 2025 commercial launch and has extended its cash runway into 2026.
March 19, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precigen's PRGN-2012 received FDA priority review, with a PDUFA date set for August 27, 2025. The company is preparing for a 2025 commercial launch and has extended its cash runway into 2026.
The FDA's priority review of PRGN-2012 is a significant regulatory milestone, indicating potential for approval and commercial launch in 2025. This news is likely to positively impact PGEN's stock as it suggests progress towards revenue generation. The extended cash runway into 2026 further supports the company's financial stability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100